BioDrone Therapeutics Inc.
  • Home
  • About Us
  • Our Sciences
    • Cell-Derived Vesicle
    • BioDrone™ Platform
    • Manufacturing
    • Intellectual Properties
  • Pipeline
  • Publications
    • Publications
    • Posters & Presentations
  • Business
    • Business Model
    • Open Innovation
  • News
    • Press Releases
  • More
    • Home
    • About Us
    • Our Sciences
      • Cell-Derived Vesicle
      • BioDrone™ Platform
      • Manufacturing
      • Intellectual Properties
    • Pipeline
    • Publications
      • Publications
      • Posters & Presentations
    • Business
      • Business Model
      • Open Innovation
    • News
      • Press Releases
BioDrone Therapeutics Inc.
  • Home
  • About Us
  • Our Sciences
    • Cell-Derived Vesicle
    • BioDrone™ Platform
    • Manufacturing
    • Intellectual Properties
  • Pipeline
  • Publications
    • Publications
    • Posters & Presentations
  • Business
    • Business Model
    • Open Innovation
  • News
    • Press Releases
data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs=

BIODRONE PLATFORM TECHNOLOGY

BIODRONE PLATFORM TECHNOLOGY BIODRONE PLATFORM TECHNOLOGY BIODRONE PLATFORM TECHNOLOGY


Smart drug delivery platform based on cell-derived vesicles 

Learn more

BIODRONE PLATFORM TECHNOLOGY

BIODRONE PLATFORM TECHNOLOGY BIODRONE PLATFORM TECHNOLOGY BIODRONE PLATFORM TECHNOLOGY


Smart drug delivery platform based on cell-derived vesicles 

Learn more

Latest News

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

Nov 7, 2022  MDimune, Inc. announced a business agreement with EUMC and acquisition of IP from EUMC to develop therapeutics for inflammatory bowel diseases (IBD). 

Find out more

MDimune and SensoryCure announce a collaboration to develop therapeutics for hearing loss

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

Oct 24, 2022  MDimune, Inc. enters into an MOU with SensoryCure to collaborate on the development of therapeutics for hearing loss .

Find out more

Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer

Sep 15, 2022  Caravan Biologix and MDimune announced their collaboration to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.

Find out more

About Us

BioDrone™ Platform Technology

BioDrone™ Platform Technology

BioDrone™ Platform Technology

Groundbreaking drug delivery platform that precisely delivers various drugs to targeted lesions by loading them into cell-derived vesicles (CDVs) derived from human cells.

Business Model

BioDrone™ Platform Technology

BioDrone™ Platform Technology

MDimune is currently seeking partners for R&D collaborations that utilize the BioDrone™ (CDVs) platform for next-generation cell therapies or targeted payload delivery.

Open Innovation

BioDrone™ Platform Technology

Open Innovation

Platform Inside Development Outside (PIDO) model to collaborate with pharma/biotech partners in diverse therapeutic areas (cancer, rare diseases, CNS disorders, etc.).

Photo Gallery

Cryo-TEM images of CDVs and EVs

    Copyright © 2022 BioDrone Therapeutics Inc. - All Rights Reserved.

    • Contact